Complexation of the interferon inducer, bropirimine, with hydroxypropyl-β-cyclodextrin

被引:15
作者
Echezarreta-López, M
Torres-Labandeira, JJ
Castiñeiras-Seijo, L
Santana-Penín, L
Vila-Jato, JL
机构
[1] Univ Santiago de Compostela, Fac Farm, Dept Farm & Tecnol Farmaceut, E-15706 Santiago, Spain
[2] Univ Santiago de Compostela, Fac Farm, Dept Quim Organ, E-15706 Santiago, Spain
关键词
bropirimine; cyclodextrin complexation; hydroxypropyl-beta-cyclodextrin; inclusion complex; characterization; solubility;
D O I
10.1016/S0928-0987(99)00081-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bropirimine (ABPP) is an orally active immunomodulator that increases endogenous alpha-interferon and other cytokines used clinically against carcinoma in situ of the bladder. The oral absorption of ABPP is poor because its low solubility in water. The purpose of this study is to develop a technological procedure useful to increase the water solubility of ABPP. To this end, the interaction of ABPP with several cyclodextrin derivatives-alpha-, beta-, gamma- and hydroxypropyl-beta-cyclodextrin with a degree of substitution 2.7 (HP beta CD) was studied and the effect of the complexation process on the water solubility of the drug was evaluated. The best results were obtained with the hydroxypropyl derivative, HP beta CD, that interacts in a 1:1 drug:cyclodextrin molar ratio. The inclusion complex ABPP-HP beta CD was characterized in solution by nuclear magnetic resonance (H-1 -NMR). The solid inclusion complex was obtained by freeze-drying and characterized by differential scanning calorimetry (DSC), X-ray diffractometry and mass spectrometry. The dissolution rate of ABPP from the HP beta CD solid inclusion complex was increased compared to the powdered drug but not differences were found between the complex and a physical mixture with a similar molar ratio. The increase of the dissolution rate of the drug can be attributed to the breakdown in solution of the drug dimers in the presence of the cyclodextrin and to the complex formation. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:381 / 386
页数:6
相关论文
共 22 条
[1]   INCLUSION COMPLEXES OF BROPIRIMINE WITH BETA-CYCLODEXTRIN IN SOLUTION AND IN SOLID-STATE [J].
AHMED, SM ;
NAGGI, A ;
GUERRINI, M ;
FOCHER, B .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1991, 77 (2-3) :247-254
[2]   COMPARATIVE DISSOLUTION CHARACTERISTICS OF BROPIRIMINE-BETA-CYCLODEXTRIN INCLUSION COMPLEX AND ITS SOLID DISPERSION WITH PEG-6000 [J].
AHMED, SM ;
ABDELRAHMAN, AA ;
SALEH, SI ;
AHMED, MO .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 96 (1-3) :5-11
[3]  
Ahn HJ, 1997, DRUG DEV IND PHARM, V23, P397
[4]   FORMULATION STUDIES ON [2-AMINO-5-BROMO-6-PHENYL-4(3)-PYRIMIDINONE] (ABPP), AN INTERFERON INDUCER, ANTI-CANCERIGENIC AGENT [J].
ALPAR, HO ;
WHITMARSH, SJ ;
ISMAIL, H ;
IRWIN, WJ ;
SLACK, JA ;
BELAID, KA ;
STEVENS, MFG .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1986, 12 (11-13) :1795-1811
[5]   Improvement of the in vitro dissolution of praziquantel by complexation with α-, β- and γ-cyclodextrins [J].
Becket, G ;
Schep, LJ ;
Tan, MY .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 179 (01) :65-71
[6]  
BREWSTER ME, 1989, J PARENT SCI TECHN, V43, P231
[7]   Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: Comparison with commercially available tablets and suspensions [J].
Brewster, ME ;
Anderson, WR ;
Meinsma, D ;
Moreno, D ;
Webb, AI ;
Pablo, L ;
Estes, KS ;
Derendorf, H ;
Bodor, N ;
Sawchuk, R ;
Cheung, B ;
Pop, E .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (03) :335-339
[8]   SAFETY OF PARENTERAL HYDROXYPROPYL-BETA-CYCLODEXTRIN [J].
CARPENTER, TO ;
GERLOCZY, A ;
PITHA, J .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (02) :222-225
[9]  
de Repentigny L, 1998, ANTIMICROB AGENTS CH, V42, P404
[10]   SMALL-INTESTINAL ABSORPTION OF BROPIRIMINE IN RATS AND EFFECT OF BILE-SALT ON THE ABSORPTION [J].
EMORI, H ;
YOKOHAMA, S ;
NISHIHATA, T .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (06) :487-492